Iovance Biotherapeutics Inc.

IOVA | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.19

-$0.06 (-0.59%)

At close: Sep 21, 2026, 4:00 PM ET

$10.20

+$0.01 (+0.10%)

Pre-market: Sep 22, 2026, 8:49 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.59%

(1D)

Rating

Updated: Sep 10, 2026

34.4

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $4.55B

1D Range

10.04 10.64

52W Range

1.76 10.98

Valuation (TTM)

PE -14.56

PB 6.18

EV/EBITDA -16.36

Valuation (NTM)

Forward PE N/A

Forward PEG 0.28

Price Target $8.17

Cash Flow

FCF Yield -6.5%

SBC Adj. FCF Yield -7.5%

SBC Impact -15.8%

Margins

Gross Margin 116.3%

Operating Margin -92.7%

FCF Margin -91.2%

Growth (CAGR)

Revenue 3Y | 5Y 1009.4% | 74.3%

Dil EPS 3Y | 5Y 40.4% | 26.6%

FCF 3Y | 5Y 15.3% | 0.9%

Returns

ROA -31.6%

ROE -40.5%

ROIC -36.6%

Financial Health

Net Cash

$297.67M

Current Ratio 4.35

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission inv...

Sector Healthcare

Industry Biotechnology

Employees 975

IPO Date Oct 14, 2010

Website www.iovance.com

Fiscal Year January - December

Full Company Profile

Latest News

3 days ago · globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance's common stock to eighteen new, non-executive employees.

5 days ago · defenseworld.net

Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)

Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Analyst Recommendations This is a breakdown of current ratings

7 days ago · defenseworld.net

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week High – Time to Buy?

Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $9.41 and last traded at $9.26, with a volume of 21030162 shares. The stock had previously closed at $8.60. Analysts Set New Price Targets A number of brokerages

18 days ago · globenewswire.com

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:

1 month ago · benzinga.com

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?

Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.

1 month ago · benzinga.com

Why Iovance Biotherapeutics Stock Hit 52-Week High

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%.

1 month ago · zacks.com

Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · seekingalpha.com

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates

Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.